Shore Capital Reiterates “House Stock” Rating for Begbies Traynor Group (LON:BEG)

Shore Capital restated their house stock rating on shares of Begbies Traynor Group (LON:BEG) in a research report released on Tuesday, Marketbeat Ratings reports.

Separately, Canaccord Genuity Group cut their price target on Begbies Traynor Group from GBX 175 ($2.31) to GBX 158 ($2.09) and set a buy rating for the company in a report on Tuesday, July 9th.

Begbies Traynor Group Trading Down 1.0 %

Shares of LON:BEG opened at GBX 101 ($1.33) on Tuesday. The company’s 50-day moving average is GBX 101.52 and its 200 day moving average is GBX 104.61. The company has a current ratio of 1.31, a quick ratio of 1.35 and a debt-to-equity ratio of 23.79. The company has a market cap of £159.86 million, a P/E ratio of 10,100.00, a PEG ratio of 2.95 and a beta of 0.37.

Begbies Traynor Group Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, November 6th. Stockholders of record on Thursday, October 10th will be given a dividend of GBX 2.70 ($0.04) per share. This represents a dividend yield of 2.72%. This is an increase from Begbies Traynor Group’s previous dividend of $1.30. The ex-dividend date is Thursday, October 10th. Begbies Traynor Group’s dividend payout ratio (DPR) is 40,000.00%.

About Begbies Traynor Group

Begbies Traynor Group plc provides various professional services to businesses, professional advisors, large corporations, and financial institutions in the United Kingdom. The company operates through two segments: Insolvency and Advisory Services; and Property Advisory and Transactional Services. It offers business rescue and recovery services, including company administration, creditors' voluntary liquidation, company dissolution and strike off, company voluntary arrangement, compulsory liquidation, the Law of Property Act or fixed charge receiverships, members' voluntary liquidation, partnership liquidation, and personal insolvency services, as well as closure options for insolvent companies.